GlobalData, the industry analysis specialist, has released its new conference alerts, European Society of Cardiology Congress 2011 Post-Conference Review and Analysis. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.
The report provides complete coverage of conference. Its scope includes
- Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
- Review of preand post-conference KOL/analyst comments
- Market revenue data for 2010 and forecast forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
- Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
- Explore M&A opportunities by identifying key products and market players.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the market opportunities.
- Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.
Table of content
1 Table of contents
1 Table of contents 3
1.1 List of Tables 3
1.2 List of Figures 3
2 European Society of Cardiology Congress 2011 - Post-Conference Highlights 4
2.1 ARISTOTLE - Efficacy and Safety of Apixaban Compared to Warfarin for Prevention of Stroke and Systemic Embolism in 18,202 Patients with Atrial Fibrillation - Primary Results of the ARISTOTLE Trial 4
2.2 Efficacy And Safety Of The Novel Oral Factor Xa Inhibitor Apixaban In Atrial Fibrillation (Af) Patients With Chronic Kidney Disease (Ckd) - The Averroes Trial 5
2.3 TRV120027, a Novel beta-Arrestin Biased Ligand at the Angiotensin II type I Receptor, Unloads the Heart and Maintains Renal Function when added to Furosemide in Experimental Heart Failure 6
2.4 Cardiorenal Actions of the Designer Natriuretic Peptide, CD-NP, in a Severe Heart Failure model Treated with Furosemide. 7
2.5 Effect of Specific ADRB1/ADRB2/AGT Genotype Combinations on the Association Between Survival and Carvedilol Treatment in Chronic Heart Failure 8
2.6 Double-blind, Randomized Comparison Between Zofenopril and Ramipril in Patients with LV Dysfunction Treated with ASA - the SMILE IV Study 9
2.7 Cost-effectiveness of NT-proBNP-guided Therapy in Heart Failure; Results From the TIME-CHF Study 10
2.8 Acetylsalicylic Acid Inhibits Thromboxane A2 production and Thromboxane A2-dependent Platelet Function Equally well in Diabetic and Non-Diabetic Subjects 11
2.9 Rho-Kinase Activity in Circulating Neutrophils of Patients with Vasospastic Angina - Non-Invasive Method for Diagnosis and Disease Activity Assessment 12
2.10 Intravenous Nicorandil Improves Symptoms and Left Ventricular Diastolic Function Immediately in Patients With Acute Heart Failure - a Randomized, Controlled Trial. 13
2.11 LDL-Cholesterol - The Lower, the Better - is it True For Plaque Regression? Statin Alone Versus Combination of Ezetimibe and Statin 14
2.12 In Vitro and Vivo Gene Targeting with Adenoviral Vector Conjugated Magnetic Nanobeads for Cardiac Regeneration 15
2.13 SERCA2a Gene Transfer Prevents Coronary Spasm 16
2.14 The Prohormone of B-type Natriuretic Peptide, proBNP1-108, is Secreted by the Failing and Non-failing Human Heart 17
2.15 Plasma Renin Activity and Angiotensinogen M235T Polymorphism are Determinants of Aldosterone Escape in Patients with Systolic Heart Failure 18
2.16 Three-year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on Progression of Coronary Atherosclerosis; Evaluation by IntraVascular UltraSound) Trial 19
2.17 Benefits of Statin Therapy on Long Term Prognosis in Coronary Artery Disease 20
2.18 Risk of Cardiovascular Outcomes after Low-Dose Acetylsalicylic Acid Discontinuation - a UK Primary Care Study 21
2.19 Evaluation of Safety and Efficacy of Inocitol Hexanicotinic Acid (IHN) Versus Nicotinic Acid in the Treatment of Dyslipidemia 22
2.20 Angiotensin-Converting Enzyme Inhibitor Therapy in Non-Obstructive Coronary Artery Disease 23
3 Appendix 24
3.1 Abbreviations 24
3.2 Disclaimer 26
List of Table
Table 1: Olmesartan Therapy Long Term Clinical Outcomes 19
Table 2: The Risk of MI/Coronary Death and The Risk of IS/TIA Discontinuation of Low-Dose ASA 21
Table 3: HDL Change from Baseline 22
List of Chart
Figure 1: Genotype Combinations on the Association Between Survival and Carvedilol Treatment in Chronic Heart Failure (CHF) 8
Figure 2: Cost-Effectiveness of NT-proBNP-Guided Therapy in Heart Failure 10
Make an enquiry before buying this Report
Please fill the enquiry form below.